基于微观模拟的类风湿关节炎动态决策分析模型的构建及卫生经济学评价研究

71874209
2018
G0405.健康管理与政策
万小敏
面上项目
副主任药师
中南大学
49万元
微观模拟;经济学评价;类风湿关节炎;药物经济学;卫生经济
2019-01-01到2022-12-31
  • 中英文摘要
  • 结题摘要
  • 结题报告
  • 项目成果
  • 项目参与人
查看更多信息请先登录或注册
查看更多信息请先登录或注册
查看更多信息请先登录或注册
重置
序号 标题 类型 作者
1 Cost-effectiveness of first-line versus second-line pembrolizumab or chemotherapy in patients with microsatellite-instability-high/mismatch repair-deficient advanced colorectal cancer 期刊论文 Chongqing Tan;SiNi Li;Xiaohui Zeng;Liubao Peng;Ye Peng;Shuxia Qin;Liting Wang;Meiyu Wu;Xiaomin Wan
2 分区生存模型在药物经济学评价中的应用简介及实例解析 期刊论文 刘新义;谭重庆;曾小慧;彭六保;万小敏
3 Cost-Effectiveness of Lorlatinib as a First-Line Therapy for Untreated Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer 期刊论文 SiNi Li;JianHe Li;LiuBao Peng;YaMin Li;XiaoMin Wan
4 Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab for Advanced Non-Small-Cell Lung Cancer 期刊论文 Xiaomin Wan;Xiaohui Zeng;Liubao Peng;Ye Peng;Qiao Liu;Lidan Yi;Xia Luo;Qijian Deng;Chongqing Tan
5 Economic Evaluation of Dapagliflozin in the Treatment of Patients With Heart Failure: A Systematic Review 期刊论文 Meiyu Wu;Shuxia Qin;Liting Wang;Chongqing Tan;Ye Peng;Xiaohui Zeng;Xia Luo;Lidan Yi;Xiaomin Wan
6 First-line Nivolumab Plus Ipilimumab vs Sunitinib for Metastatic Renal Cell Carcinoma: A Cost-effectiveness Analysis 期刊论文 Wan Xiaomin;Zhang Yucong;Tan Chongqing;Zeng Xiaohui;Peng Liubao
7 胃癌筛查卫生经济学评价的系统评价 期刊论文 秦淑霞;易利丹;李斯妮;吴美渝;王李婷;曾小慧;谭重庆;彭六保;万小敏
8 Cost-Effectiveness Analysis of Adding Daratumumab to a Regimen of Bortezomib, Melphalan, and Prednisone in Newly Diagnosed Multiple Myeloma 期刊论文 Xiaohui Zeng;Qiao Liu;Liubao Peng;Ye Peng;Lidan Yi;Xia Luo;Sini Li;Xiaomin Wan;Chongqing Tan
9 甘草酸单铵半胱氨酸改善病毒性肝炎患者肝功能异常的药物经济学评价 期刊论文 万小敏;彭六保;曾小慧;石茵;张英杰;谭重庆
10 Cost-Effectiveness of Atezolizumab Plus Chemotherapy as First-Line Therapy for Metastatic Urothelial Cancer 期刊论文 Shuxia Qin;Lidan Yi;Sini Li;Chongqing Tan;Xiaohui Zeng;Liting Wang;Ye Peng;Xiaomin Wan
11 Cost-effectiveness of Triple Therapy vs. Biologic Treatment Sequence as First-line Therapy for Rheumatoid Arthritis Patients after Methotrexate Failure 期刊论文 SiNi Li;JianHe Li;LiuBao Peng;YaMin Li;XiaoMin Wan
12 Sequences of biological treatments for patients with moderate‑to‑severe rheumatoid arthritis in the era of treat‑to‑target in China: a cost‑effectiveness analysis 期刊论文 Chongqing Tan;Xia Luo;Sini Li;Lidan Yi;Xiaohui Zeng;Liubao Peng;Shuxia Qin;Liting Wang;Xiaomin Wan
13 Tofacitinib in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in China: A Cost-Effectiveness Analysis Based on a Mapping Algorithm Derived from a Chinese Population 期刊论文 Tan C;Li S;Yi L;Zeng X;Peng L;Qin S;Wang L;Wan X
14 Cost-Effectiveness of Baricitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis After Methotrexate Failed in China 期刊论文 SiNi Li;JianHe Li;LiuBao Peng;YaMin Li;XiaoMin Wan
15 Cost-Effectiveness Analysis of Hepatic Arterial Infusion Chemotherapy of Infusional Fluorouracil, Leucovorin, and Oxaliplatin Versus Transarterial Chemoembolization in Patients With Large Unresectable Hepatocellular Carcinoma 期刊论文 Haixia Zhang;Xiaohui Zeng;Ye Peng;Chongqing Tan;Xiaomin Wan
16 Cost-Effectiveness of Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma in the United States 期刊论文 Ye Peng;Zhihua She;Liubao Peng;Qiao Liu;Lidan Yi;Xia Luo;Sini Li;Liting Wang;Shuxia Qin;Xiaomin Wan;Chongqing Tan
17 First-Line Atezolizumab for Metastatic NSCLC with High PD-L1 Expression: A United States-Based Cost-Effectiveness Analysis 期刊论文 Ye Peng;Xiaohui Zeng;Liubao Peng;Qiao Liu;Lidan Yi;Xia Luo;Sini Li;Liting Wang;Shuxia Qin;Xiaomin Wan
18 Sintilimab Plus Bevacizumab Biosimilar Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis 期刊论文 Ye Peng;Xiaohui Zeng;Liubao Peng;Qiao Liu;Lidan Yi;Xia Luo;Sini Li;Liting Wang;Shuxia Qin;Xiaomin Wan;Chongqing Tan
19 Cost-effectiveness of Pembrolizumab plus chemotherapy as first-line therapy for advanced oesophageal cancer 期刊论文 Meiyu Wu;Shuxia Qin;Liting Wang;Chongqing Tan;Ye Peng;Xiaohui Zeng;Xia Luo;Lidan Yi;Xiaomin Wan
20 Cost-Effectiveness of Nivolumab Plus Ipilimumab Combined with Two Cycles of Chemotherapy as FirstLine Treatment in Advanced Non-Small Cell Lung Cancer 期刊论文 Ye Peng;Xiaohui Zeng;Liubao Peng;Qiao Liu;Lidan Yi;Xia Luo;Sini Li;Liting Wang;Shuxia Qin;Xiaomin Wan;Chongqing Tan
21 Clinical Benefit and Cost Effectiveness of Risk-Stratified Gastric Cancer Screening Strategies in China: A Modeling Study 期刊论文 Shuxia Qin;Xuehong Wang;Sini Li;Chongqing Tan;Xiaohui Zeng;Xia Luo;Lidan Yi;Liubao Peng;Meiyu Wu;Ye Peng;Liting Wang;Xiaomin Wan
22 Cost-Effectiveness of ipilimumab plus anti-PD-1 therapy Versus ipilimumab alone in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy 期刊论文 Ye Peng;Xiaohui Zeng;Liubao Peng;Qiao Liu;Lidan Yi;Xia Luo;Sini Li;Liting Wang;Shuxia Qin;Xiaomin Wan;Chongqing Tan
23 Trametinib for patients with recurrent low-grade serous ovarian cancer: A cost-effectiveness analysis 期刊论文 Huiling Piao;Meiyu Wu;Shuxia Qin;Zhiyao Tang;Guangliang Zhou;Xiaomin Wan;Xiaocong Zuo
24 我国类风湿性关节炎治疗的药物经济学评价研究现状 期刊论文 秦淑霞;易利丹;李斯妮;王李婷;曾小慧;谭重庆;彭六保;万小敏
25 Benefit-to-harm ratio and cost-effectiveness of government-recommended gastric cancer screening in China: A modeling study 期刊论文 Shuxia Qin;Xuehong Wang;Sini Li;Chongqing Tan;Xiaohui Zeng;Meiyu Wu;Ye Peng;Liting Wang;Xiaomin Wan
26 First-line Daratumumab in Addition to Chemotherapy for Newly Diagnosed Multiple Myeloma Patients Who are Transplant Ineligible: A Cost-Effectiveness Analysis 期刊论文 Li SiNi;Li JianHe;Peng LiuBao;Tan ChongQing;Zeng XiaoHui;Peng CiYan;Zhang Chang;Li YaMin;Wan XiaoMin
27 First-Line Atezolizumab in Addition to Bevacizumab Plus Chemotherapy for Metastatic, Nonsquamous Non–Small Cell Lung Cancer: A United States–Based Cost-Effectiveness Analysis 期刊论文 Wan Xiaomin;Luo Xia;Tan Chongqing;Zeng Xiaohui;Zhang Yucong;Peng Liubao
查看更多信息请先登录或注册

相关项目

趋势报告

经验分享